Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 348

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy

Open access
Prasanna, Pataje G, Citrin, Deborah E, Hildesheim, Jeffrey, Ahmed, Mansoor M, Venkatachalam, Sundar, Riscuta, Gabriela, Xi, Dan, Zheng, Guangrong, Deursen, Jan van, Goronzy, Jorg, Kron, Stephen J, Anscher, Mitchell S, Sharpless, Norman E, Campisi, Judith, Brown, Stephen L, Niedernhofer, Laura J, O’Loghlen, Ana, Georgakilas, Alexandros G, Paris, Francois, Gius, David, Gewirtz, David A, Schmitt, Clemens A, Abazeed, Mohamed E, Kirkland, James L, Richmond, Ann, Romesser, Paul B, Lowe, Scott W, Gil, Jesus, Mendonca, Marc S, Burma, Sandeep, Zhou, Daohong, Coleman, C Norman·2021·JNCI: Journal of the National Cancer Institute

Abstract

Cellular senescence is an essential tumor suppressive mechanism that prevents the propagation of oncogenically activated, genetically unstable, and/or damaged cells. Induction of tumor cell senescence is also one of the underlying mechanisms by which cancer therapies exert antitumor activity. However, an increasing body of evidence from preclinical studies demonstrates that radiation and chemotherapy cause accumulation of senescent cells (SnCs) both in tumor and normal tissue. SnCs in tumors can, paradoxically, promote tumor relapse, metastasis, and resistance to therapy, in part, through expression of the senescence-associated secretory phenotype. In addition, SnCs in normal tissue can contribute to certain radiation- and chemotherapy-induced side effects. Because of its multiple roles, cellular senescence could serve as an important target in the fight against cancer. This commentary provides a summary of the discussion at the National Cancer Institute Workshop on Radiation, Senescence, and Cancer (August 10-11, 2020, National Cancer Institute, Bethesda, MD) regarding the current status of senescence research, heterogeneity of therapy-induced senescence, current status of senotherapeutics and molecular biomarkers, a concept of “one-two punch” cancer therapy (consisting of therapeutics to induce tumor cell senescence followed by selective clearance of SnCs), and its integration with personalized adaptive tumor therapy. It also identifies key knowledge gaps and outlines future directions in this emerging field to improve treatment outcomes for cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djab064

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 135 references

Research works printed but not linked: 4

  1. Gopal, 2019, Dynamic transdifferentiation programs in small cell lung carcinoma (Abstract nr 2897), Cancer Res, 79(suppl 13
  2. Robbins, 2021, Senolytic drugs: reducing senescent cell viability to extend health span, Annu Rev Pharmacol Toxicol, 61, 779, 10.1146/annurev-pharmtox-050120-105018 · DOI · Paper page
  3. He, 2020, Senolytics in Diseases, Ageing and Longevity. Healthy Ageing and Longevity
  4. Zakeri, 2020, Development of novel radiosensitizers through the National Cancer Institute’s Small Business Innovation Research Program, Radiat Res, 193, 425, 10.1667/RR15545.1 · doi:10.1667/rr15545.1

Cited by

See all 348

Metadata

Authors
Prasanna, P. G., Citrin, D. E., Hildesheim, J., Ahmed, M. M., Venkatachalam, S., Riscuta, G., Xi, D., Zheng, G., Deursen, J. V., Goronzy, J., Kron, S. J., Anscher, M. S., Sharpless, N. E., Campisi, J., Brown, S. L., Niedernhofer, L. J., O’Loghlen, A., Georgakilas, A. G., Paris, F., Gius, D., Gewirtz, D. A., Schmitt, C. A., Abazeed, M. E., Kirkland, J. L., Richmond, A., Romesser, P. B., Lowe, S. W., Gil, J., Mendonca, M. S., Burma, S., Zhou, D., & Coleman, C. N.
Venue
JNCI: Journal of the National Cancer Institute
Published
2021-04-01
Volume
113
Issue
10
Pages
1285-1298
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W3146830857
Cited by
348
References
135
FWCI
28.72
Type
journal article
Language
en
Open access
hybrid
Funders
  • National Cancer Institute (P30CA060553, R37CA222294, RO1 CA197796, R01 CA246807, 1R01CA214025-01, RO1CA239706, AG063543, ES029603, AG056278, P01AG062413, R01CA164492, R01CA217182, CA116021, R37CA233770, R37AG013925, R33AG061456, P30CA008748, K12 CA184746, R01CA211963, R01CA219836, R01CA242003, R01AG063801, R01CA218596, R21CA205660, BC10850)
  • National Aeronautics and Space Administration (NNX16AD78G)
  • Avon Foundation for Breast Cancer Research and the Lynn Sage Cancer Research Foundation
  • MRC (MC-U120085810)
  • Worldwide Cancer Research (18- 0215)
  • CRUK (C15075/A28647)
  • Kirkland’s laboratory
  • Alzheimer’s Association Part the Cloud Program, Robert and Arlene Kogod
  • Connor Group, Robert J. and Theresa W. Ryan
  • Noaber Foundation
  • BBSRC (BB/P000223/1)
  • Barts Charity Grant (MGU0497)
  • VA MERIT Award (101BX002301)
  • VA Senior Research Career Scientist Award
  • Deutsche Krebshilfe (110678)
  • BMBF e: Med program project SeneSys (031L0189A)
  • Deutsche Forschungsgemeinschaft DFG (GO 2688/1-1 | SCHM 1633/11-1, SCHM 1633/9-1)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy. https://app.cochat.ai/papers/10.1093/jnci/djab064
The paper
Prasanna, P. G., Citrin, D. E., Hildesheim, J., Ahmed, M. M., Venkatachalam, S., Riscuta, G., Xi, D., Zheng, G., Deursen, J. V., Goronzy, J., Kron, S. J., Anscher, M. S., Sharpless, N. E., Campisi, J., Brown, S. L., Niedernhofer, L. J., O’Loghlen, A., Georgakilas, A. G., Paris, F., . . . Coleman, C. N. (2021). Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djab064

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.